Related Experiment Videos
Corticosteroids in infant chronic lung disease
1Guy's, King's and St Thomas' School of Medicine, King's College London. anne.greenough@kcl.ac.uk
Summary
Corticosteroids given early after birth can reduce chronic lung disease (CLD) in infants but carry risks. Further research is needed for safer, more effective treatments for CLD.
Area of Science:
- Neonatology
- Pediatric Pulmonology
- Perinatal Medicine
Background:
- Chronic lung disease (CLD) is an increasing concern in premature infants, leading to significant respiratory morbidity and healthcare utilization.
- Current management strategies have largely failed to effectively reduce CLD incidence.
- Early systemic corticosteroids show promise in reducing CLD and improving survival but are associated with adverse side effects and neurodevelopmental concerns.
Purpose of the Study:
- To review the current evidence on the efficacy and safety of corticosteroids in preventing and treating CLD in neonates.
- To identify knowledge gaps regarding optimal corticosteroid use and alternative therapies for CLD.
Main Methods:
- Systematic review of randomized controlled trials and observational studies.
- Analysis of data on CLD incidence, mortality, side effects, and long-term neurodevelopmental outcomes.
Main Results:
- Systemic corticosteroids administered within the first two weeks of life reduce CLD and may improve survival.
- Inhaled corticosteroids have fewer adverse effects but are less effective than systemic administration.
- Significant concerns remain regarding the acute side effects and long-term neurodevelopmental impact of systemic corticosteroids.
Conclusions:
- While early systemic corticosteroids offer a benefit in reducing CLD, their adverse effects necessitate careful consideration.
- There is a critical need for further research to identify high-risk infants, optimize corticosteroid dosage for a favorable risk-benefit ratio, and develop safer, more effective alternative therapies for CLD.